Last reviewed · How we verify
A Mass Balance Study to Investigate the Metabolic Disposition of a 400 mg Single, Oral Dose of GSK189075 in Healthy Male Subjects
This study will look at the relative amounts of GSK189075 that are found in samples of blood, urine, and feces of healthy male volunteers. Results of the study will be used to understand how the drug is converted in the body and how it is eliminated.
Details
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 8 |
| Start date | 2006-11 |
Conditions
- Type 2 Diabetes Mellitus
- Diabetes Mellitus, Type 2
Interventions
- Radiolabelled GSK189075
Primary outcomes
- Laboratory tests to determine the amount of radiolabelled drug that is found in blood, urine, and feces. Blood samples at Days 1-5. — at Days 1-5.
- Urine & Fecal collection at Day -1 & days 1-5. — at Day -1 & days 1-5.
Countries
United States